KEI asks FTC to block Celgene Acquisition of Juno​ Therapeutics, over BCMA-targeted CAR T treatment for Multiple Myeloma

On February 14, 2018, KEI meet with the FTC to express our opposition to Celgene’s proposed acquisition of Juno Therapeutics.


The Celgene acquisition of Juno Therapeutics would give Celgene control over competing
candidates for the treatment of multiple myeloma that use B-cell maturation antigen (BCMA)
CAR T technologies from two companies that benefits from NIH funded research, Bluebird Bio and Juno Therapeutics. KEI asks that the FTC either block the acquisition, or require Celgene to
divest the competing BCMA technologies to an independent third party.